Evidence map›Paper›PMID 34570291›Full record

ReviewCurrent oncology reports2021

Interventional Strategies in Cancer-induced Cardiovascular Disease.

Bala Pushparaji, Teodora Donisan, Dinu V Balanescu, Nicolas Palaskas, Peter Kim, Juan Lopez-Mattei, Mehmet Cilingiroglu, Saamir A Hassan, Konstantinos Dean Boudoulas, Konstantinos Marmagkiolis and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Bala PushparajiDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1451, Houston, TX, 77030, USA.
Teodora DonisanDepartment of Internal Medicine, Beaumont Hospital, Royal Oak, MI, USA.
Dinu V BalanescuDepartment of Internal Medicine, Beaumont Hospital, Royal Oak, MI, USA.
Nicolas PalaskasDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1451, Houston, TX, 77030, USA.
Peter KimDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1451, Houston, TX, 77030, USA.
Juan Lopez-MatteiDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1451, Houston, TX, 77030, USA.
Mehmet CilingirogluDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1451, Houston, TX, 77030, USA.
Saamir A HassanDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1451, Houston, TX, 77030, USA.
Konstantinos Dean BoudoulasThe Ohio State University Wexner Medical Center, Columbus, OH, USA.
Konstantinos MarmagkiolisDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1451, Houston, TX, 77030, USA.
Ludhmila Abrahao HajjarInstituto Do Coração, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Cezar A IliescuDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1451, Houston, TX, 77030, USA. ciliescu@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USBeaumont Hospital, Royal Oak · USBahçeşehir University · TRHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRNorthside Hospital · USThe Ohio State University Wexner Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewTo highlight the range of illnesses and procedures that the interventional onco-cardiologists face in their daily practice, along with the recent additions to anti-cancer therapies and their related cardiotoxicity. RECENT

findingsImmune checkpoint inhibitors (ICI) are not devoid of cardiotoxicity as thought earlier and lead to an increased incidence of myocarditis. Transcatheter valve replacement has been shown to be a safer alternative to surgical replacement in cancer patients. Interventional onco-cardiology is a novel field that addresses cardiovascular diseases in the setting of cancer. Traditionally excluding cancer patients from clinical trials has led to a dearth of information needed to tackle cardiac conditions like Takotsubo cardiomyopathy, malignant pericardial effusions, and radiation-induced vascular diseases encountered either exclusively or predominantly in this high-risk population. This review discusses the various treatment options available in the interventional armamentarium with a particular focus on ICI-myocarditis and transcatheter aortic valve replacement in cancer patients.

Indexed as

CardiotoxicityCardiovascular DiseasesHumansImmune Checkpoint InhibitorsMyocarditisNeoplasmsTakotsubo CardiomyopathyTranscatheter Aortic Valve ReplacementImmune Checkpoint InhibitorsAcute coronary syndromeCarcinoid heart diseaseCardio-oncologyCoronary artery diseaseInterventional onco-cardiologyPercutaneous coronary interventionPericardiocentesisTakotsubo cardiomyopathyTranscatheter aortic valve replacement

Identifiers

PMID34570291
OpenAlexW3204140426

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.